Characteristics of Included Studies
| First author (year) | T & C sample (female, %) | Age distribution (mean) | BMI (mean) | Course of disease (mean) | Tx methods | Tx periods | Evaluation methods | Adverse event | Outcome (%) & P-value | |
|---|---|---|---|---|---|---|---|---|---|---|
| Chen Y12)(2008) | T: 40 (45.0) | NR(57.4±7.1) | BMI>28 | 0.6-32y | 1st grade: 15 | HM (OA)+norvasc | 4w | 1. Anti-hypertensive efficacy standards - Effective: diastolic blood pressure drop by 10 mmHg or more (within the normal range); or drop by more than 20 mmHg - Improved: diastolic blood pressure drop by less than 10 mmHg (within the normal range); or 10-19 mmHg drop (not within the normal range); or systolic blood pressure drop by more than 30 mmHg - Ineffective: those who do not meet the above standards 2. Comparison of symptom efficacy - Cured: disappeared 90%↑ - Effective: disappeared 70%↑ - Improved: disappeared 50-70% - Ineffective: disappeared 50%↓ 3. Blood pressure |
NR | 1. T>C: 92.5%>72.5%(P<0.05) 2. T>C:95.0%>65.0%(P<0.01) |
| 2nd grade: 16 | ||||||||||
| 3rd grade: 9 | ||||||||||
| C: 40 (42.5) | NR(56.8±6.9) | 0.5-30y | 1st grade: 17 | Norvasc | ||||||
| 2nd grade: 16 | ||||||||||
| 3rd grade: 7 | ||||||||||
| Zhao H13)(2016) | T: 40 (72.5) | NR(62.3±9.3) | BMI>28(31.0±1.3) | NR | 1st grade: 14 | HM (OA)+valsartan | 12w | 1. TCM syndrome score and curative effect evaluation - Effective: the blood pressure control reaches to normal range, symptoms basically disappear, and the symptom score is reduced by 70%↑ - Improved: the blood pressure control reaches to normal range, symptoms are significantly improved, and the symptom score is reduced by 30-70% - Ineffective: the blood pressure control does not reach to normal range or unstable, no improvement in symptoms and signs, and symptom score is reduced by 30%↓ 2. Blood pressure 3. BMI 4. TC, TG, HDL, LDL 5. FINS, FBG, IRI |
NR | 1. T>C: 95%>82.5%(P<0.01) |
| 2nd grade: 26 | ||||||||||
| C: 40 (55.0) | NR(64.2±8.7) | BMI>28(30.9±1.8) | 1st grade: 19 | Valsartan | ||||||
| 2nd grade: 21 | ||||||||||
| Li S14)(2018) | T: 44(45.4) | NR(61.3±8.4) | BMI>28(30.4±8.3) | NR | HM (OA)+irbesartan | 4w | 1. Blood pressure 2. BMI 3. TC, TG, HDL, LDL |
NR | ||
| C: 44(47.7) | NR(61.5±8.5) | BMI>28(30.6±8.2) | Irbesartan | |||||||
| Liu S15)(2020) | T: 45(53.3) | 32-72 (53.8±2.1) | BMI≥28 | 1-19y(0.5±0.7) | HM (OA) | 28d | 1. TCM symptom score evaluation scale - Integral evaluation scores (0 to 4) indicate the increasing trend of symptoms |
NR | ||
| C: 45(48.8) | 35-71(54.0±2.2) | 2-20y(0.5±0.7) | Valsartan | |||||||
| Qian H16) (2020) | T: 32(37.5) | 34-75(56.3±4.6) | BMI≥28(33.6±2.6) | 2-14y(7.0±1.2) | 1st grade: 10 | HM (OA)+amlodipine | 4w | 1. Anti-hypertensive efficacy standards - Effective: diastolic blood pressure drop by 10 mmHg or more (within the normal range); or drop by more than 20 mmHg - Improved: diastolic blood pressure drop by less than 10 mmHg (within the normal range); or 10-19 mmHg drop (not within the normal range); or systolic blood pressure drop by more than 30 mmHg - Ineffective: those who do not meet the above standards 2. Blood pressure 3. BMI 4. Adverse events and drug safety |
None | 1. T>C:96.9%>84.4%(P<0.05) |
| 2nd grade: 22 | ||||||||||
| C: 32(40.6) | 30-73(55.6± 5.2) | BMI≥28(34.1±2.4) | 3-12y(6.1±2.1) | 1st grade: 11 | Amlodipine | |||||
| 2nd grade: 21 | ||||||||||
| Zhu C17)(2022) | T: 100(42.0) | 30-65(51.3±8.5) | BMI≥28(30.9±2.6) | NR | HM (OA)+ anti-hypertensive drugs+diet | 12w | 1. Anti-hypertensive efficacy standards - Effective: diastolic blood pressure drop by 10 mmHg or more (within the normal range); or drop by more than 20 mmHg - Improved: diastolic blood pressure drop by less than 10 mmHg (within the normal range); or 10-19 mmHg drop (not within the normal range); or systolic blood pressure drop by more than 30 mmHg - Ineffective: those who do not meet the above standards 2. Blood pressure 3. BMI 4. Comparison of major cardiovascular adverse events and drug safety |
None | 1. T>C: 80%>46%(P<0.05) | |
| C: 100(40.0) | 29-66(51.6±8.5) | BMI≥28(30.8±2.8) | Anti-hypertensive drugs+diet | |||||||
| Fan L18)(2022) | T: 40(42) | 56.1±7.1 | BMI≥28 | 4.8±1.1 | HM (OA)+irbesartan+(amlodipine) | 8w | 1. TCM clinical efficacy - Effective: disappeared 70%↑ - Improved: disappeared 30-70% - Ineffective: disappeared 30%↓ 2. TCM syndrome score and curative effect evaluation - 0: None - 1: light - 2: medium - 3: heavy 3. Irisin levels, LEP, ADP, FBG, TG, TC and LDL 4. WT, WC, Blood pressure 5. Adverse events and drug safety |
None | 1. T>C: 82.5%>60.0%(P<0.05) | |
| C: 40(40) | 57.3±7.6 | 5.3±1.4 | Irbesartan+(amlodipine) | |||||||
T: treatment group, C: control group, BMI: body mass index, Tx: treatment, NR: not reported, y: year(s), HM: herbal medicine, OA: oral administration, w: week(s), TCM: traditional chinese medicine, TC: total cholesterol, TG: triglyceride, HDL: high density lipoprotein, LDL: low density lipoprotein， FINS: fasting insulin, FBG: fasting blood glucose, IRI: insulin resistance index, d: day(s), LEP: leptin, ADP: adiponectin, WT: weight, WC: waist circumference.
